ARTICLES BY ERIN HARRIS
-
Cell & Gene: The Podcast Post-Episode Recap: Vor Bio’s Dr. Robert Ang4/26/2024
Welcome to my new article series, Cell & Gene: The Podcast Post-Episode Recap, which shares highlights, quotes, and more from recently aired episodes of Cell & Gene: The Podcast.
-
2024: The Year of Development in Cell Therapy4/10/2024
We break down three trends driving development in cell therapy in 2024.
-
Nanoscope Therapeutics Tackling Vision Loss With Ocular Gene Therapy3/27/2024
Leaders from Nanoscope Therapeutics explain the safety and efficacy data from as well as next steps for the company's RESTORE trial.
-
ICYMI: Q1 2024’s Cell & Gene Live And Cell & Gene: The Podcast3/27/2024
With Q1 of 2024 coming to close, I wanted to take this opportunity to make sure you’ve read, heard, or viewed some of insightful content we’ve created for Cell & Gene's readers since the start of the year.
-
Inside Tenaya Therapeutics’ AAV9-Based Gene Therapy3/27/2024
Tenaya Therapeutics' CSO explains how the company's gene therapy, TN-401, may treat heart disease.
-
Rare Disease Day 20242/29/2024
Today is Rare Disease Day 2024, a global initiative to raise awareness and generate support for everyone who is on a rare medical journey.
-
Video Clips From Cell & Gene Live: 2024 Regulatory Outlook With FDA's Dr. Peter Marks And Dr. Nicole Verdun2/27/2024
Our recent Cell & Gene Live, 2024 Regulatory Outlook With FDA's Drs. Peter Marks and Nicole Verdun, was a chock full of data and valuable information. I've broken down the full-length presentation into bite sized video clips that you can view at your convenience.
-
Inside Cell & Gene Live “How To Reduce Batch-To-Batch Variation In Cell Therapy Manufacturing”2/26/2024
Here's a recap of our recent Cell & Gene Live, How to Reduce Batch-to-Batch Variation in Cell Therapy Manufacturing, featuring expert panelists, Omkar Kawalekar, Ph.D., Head of Manufacturing and Supply Chain at NextGen Therapies Consulting at Deloitte and Donna Rill, Chief Technology Officer at Triumvira Immunologics.
-
Mass General Cancer Center’s Dr. Genevieve Boland on Amtagvi Approval2/26/2024
The FDA’s approval of Amtagvi addresses an unmet need in melanoma patient care. Here, Genevieve Boland, M.D., Ph.D., from Mass General Cancer Center shares her insight on the approval.
-
Inside Cell & Gene Live “2024 Regulatory Outlook With FDA’s Dr. Peter Marks And Dr. Nicole Verdun”1/30/2024
In case you missed it, our recent Cell & Gene Live, 2024 Regulatory Outlook with FDA’s Dr. Peter Marks and Dr. Nicole Verdun, is available on demand. Here's a summary of the event.